Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AZD5492

Bispecific antibody (Multispecific) · Immune activation, directed at CD20 (MS4A1), CD3 (CD3E) and CD8 (CD8A) · developed by ASTRAZENECA

Phase 1/2 Most advanced trial

AZN Developer

1 Registered trials

What is AZD5492?

AZD5492 is a trispecific IgG-like T-cell engaging antibody that binds CD20 on tumor B-cells and CD3 and CD8 on T-lymphocytes. Cross-linkage triggers a cytotoxic T-lymphocyte response against CD20-expressing tumor cells. It is studied in B-cell malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Bispecific antibody (Multispecific)
Targets: CD20 (MS4A1), CD3 (CD3E), CD8 (CD8A)
Mechanism: Immune activation, directed at CD20 (MS4A1), CD3 (CD3E) and CD8 (CD8A)
Pathways: cytotoxic T-lymphocyte response
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06542250	Phase 1/2	B-cell Malignancies	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Malignancies

Other drugs acting on MS4A1 / CD3E / CD8A

Anti-Thymocyte Globulin FDA approved Blinatumomab FDA approved CT-95 Phase 1 Foralumab Phase 2 Gocatamig Phase 1/2 Imvotamab Phase 1/2 Mipletamig Phase 1 MK-1045 Phase 2/3 Odronextamab Phase 2/3 TAK-186 Phase 1/2 TL011 Phase 1

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD5492

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z